Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial

. 2025 Mar 28 ; 27 (4) : .

Jazyk angličtina Země Velká Británie, Anglie Médium print

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III

Perzistentní odkaz   https://www.medvik.cz/link/pmid40132102

Grantová podpora
InCarda Therapeutics Inc

AIMS: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. New treatments are needed to cardiovert recent-onset paroxysmal AF quickly and safely. RESTORE-1 was a multicentre, randomized, double-blind, placebo-controlled trial of a 120 mg orally inhaled solution of flecainide acetate (FlecIH-103) for cardioversion of symptomatic, recent-onset (≤48 h) paroxysmal AF. The study aim was to evaluate the efficacy and safety of FlecIH-103 administered via oral inhalation. METHODS AND RESULTS: Patients experiencing a recent-onset paroxysmal AF episode were randomized to receive a single dose of FlecIH-103 or placebo delivered over two 3.5 min inhalation periods, while patients were monitored using 12-lead electrocardiograms and Holter. The trial was stopped prematurely after treating 55 patients, due to lower-than-expected conversion rates and plasma levels. Mean age was 59.6 years, 31.5% of patients were female, and 59.2% were having their first AF episode. Conversion rate was 30.8% (95% confidence interval: 14.7-43.8) for the active group (n = 39) and 0.0% for the placebo group (n = 12) (P = 0.04). Median time to conversion was 12.8 min (IQR: 17.2). In the active group, the mean flecainide plasma level was 198 ng/mL (SD: 156), which is ∼50% lower than in the previous studies. The most common adverse events (AEs) were dysgeusia, dyspnoea, and cough. All AEs were short-lasting and of mild or moderate intensity. CONCLUSION: Despite early termination of the trial, FlecIH-103 was significantly more effective than placebo in cardioverting AF. Safety data did not show any serious AEs. Further studies of FlecIH-103 are needed to optimize the combination of drug formulation and inhalation delivery platform. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov, unique identifier: NCT05039359.

Komentář v

PubMed

Zobrazit více v PubMed

Schnabel  RB, Yin  X, Gona  P, Larson  MG, Beiser  AS, McManus  DD  et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet  2015;386:154–62. PubMed PMC

Iwasaki  Y, Nishida  K, Kato  T, Nattel  S. Atrial fibrillation pathophysiology. Circulation  2011;124:2264–74. PubMed

Martín  A, Coll-Vinent  B, Suero  C, Fernández-Simón  A, Sánchez  J, Varona  M  et al.  Benefits of rhythm control and rate control in recent-onset atrial fibrillation: the HERMES-AF study. Acad Emerg Med  2019;26:1034–43. PubMed

Mohamed  MS, Hashem  A, Khalouf  A, Osama  M, Pendela  VS, Rai  D  et al.  Delayed vs early cardioversion in patients with paroxysmal atrial fibrillation: a population-based study (2015–2020). Future Cardiol  2023;19:441–52. PubMed

Khan  IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol  2003;87:121–8. PubMed

Crijns  HJGM, Van Wijk  LM, Van Gilst  WH, Kingma  JH, Van Gelder  IC, Lie  KI. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J  1988;9:634–8. PubMed

Capucci  A, Boriani  G, Botto  GL, Lenzi  T, Rubino  I, Falcone  C  et al.  Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol  1994;74:503–5. PubMed

Alp  N, Bell  J, Shahi  M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart  2000;84:37–40. PubMed PMC

Ibrahim  OA, Belley-Côté  EP, Um  KJ, Baranchuk  A, Benz  AP, Dalmia  S  et al.  Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. Europace  2021;23:1200–10. PubMed

Markey  GC, Salter  N, Ryan  J. Intravenous flecainide for emergency department management of acute atrial fibrillation. J Emerg Med  2018;54:320–7. PubMed

Verrier  RL, Bortolotto  AL, Silva  BA, Marum  AA, Stocco  FG, Evaristo  E  et al.  Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model. Heart Rhythm  2018;15:1882–8. PubMed

Verrier  RL, Belardinelli  L. Pulmonary delivery of antiarrhythmic drugs for rapid conversion of new-onset atrial fibrillation. J Cardiovasc Pharmacol  2020;75:276–83. PubMed PMC

Crijns  HJGM, Elvan  A, Al-Windy  N, Tuininga  YS, Badings  E, Aksoy  I  et al.  Open-label, multicenter study of flecainide acetate oral inhalation solution for acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm. Circ Arrhythm Electrophysiol  2022;15:e010204. PubMed

Ruskin  JN, Camm  AJ, Dufton  C, Woite-Silva  AC, Tuininga  Y, Badings  E  et al.  Orally inhaled flecainide for conversion of atrial fibrillation to sinus rhythm: INSTANT phase 2 trial. JACC Clin Electrophysiol  2024;10:1021–33. PubMed

Joglar  JA, Chung  MK, Armbruster  AL, Benjamin  EJ, Chyou  JY, Cronin  EM  et al.  2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation  2024;149:e1–156. PubMed PMC

Alboni  P, Botto  GL, Baldi  N, Luzi  M, Russo  V, Gianfranchi  L  et al.  Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket”. Approach. New England Journal of Medicine  2004;351:2384–91. PubMed

Reiffel  JA, Blomström-Lundqvist  C, Boriani  G, Goette  A, Kowey  PR, Merino  JL  et al.  Real-world utilization of the pill-in-the-pocket method for terminating episodes of atrial fibrillation: data from the multinational antiarrhythmic interventions for managing atrial fibrillation (AIM-AF) survey. Europace  2023;25:euad162. PubMed PMC

Lévy  S, Maarek  M, Coumel  P, Guize  L, Lekieffre  J, Medvedowsky  JL  et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation  1999;99:3028–35. PubMed

Freeman  JV, Simon  DN, Go  AS, Spertus  J, Fonarow  GC, Gersh  BJ  et al.  Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes  2015;8:393–402. PubMed

National Library of Medicine; National Institutes of Health; U.S. Department of Health and Human Services. FLECAINIDE ACETATE tablet . Package Insert [Internet]. Aurobindo Pharma Limited. 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e89448-3a18-42e3-8537-2589be1ef94e (cited 11 February 2023)

Suttorp  MJ, Kingma  JH, Jessurun  ER, Lie-A-Huen  L, van Hemel  NM, Lie  KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol  1990;16:1722–7. PubMed

Roy  D, Pratt  CM, Torp-Pedersen  C, Wyse  DG, Toft  E, Juul-Moller  S  et al.  Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation  2008;117:1518–25. PubMed

Roy  D, Rowe  BH, Stiell  IG, Coutu  B, Ip  JH, Phaneuf  D  et al.  A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol  2004;44:2355–61. PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05039359

Najít záznam

Citační ukazatele

Možnosti archivace